📊 Score Breakdown
Offering Ability
80
Cash Runway
95
Float Risk
77
Warrant Exposure
50
Convertible Debt—
🌦️ Dilution Forecast
🌩️
Severe
Multiple high-probability dilution events detected
67%
💰 Capital Raise
93%
• Critical: only 1.7 months cash remaining
• Active shelf registration ($30M, 67% of market cap)
🔁 Convertible Conversion
60%
• Major convertible overhang: 103% potential dilution
• Convertible risk score very high (85/100)
📜 Warrant Exercise
15%
• Warrant overhang: 10.6% of shares outstanding
💹 Market Data
Market Cap$44.89M
Shares Outstanding7.16M
Float1.67M
Cash$1.95M
Debt$13.35M
Short InterestN/A
🏛 Institutional Holdings
QoQ: ↑ 27.7% shares (2025Q4 vs prior)
30 institutional holders · 1.96M shares
#1
FIRST MANHATTAN CO. LLC.
714.1K shares
#2
VANGUARD GROUP INC
342.2K shares
#3
UBS Group AG
219.8K shares
+ 17 more holders Sign up free to view →
📉 Short Interest
Short Interest17.7K
Days to Cover1.2
% of Float1.1%
FINRA data as of Apr 30, 2026
📁 Recent SEC Activity
xbrl
XBRL CONVERTIBLE
Sep 30, 2025
xbrl
XBRL WARRANT
Feb 18, 2025
424B3
ATM
Apr 29, 2026
EFFECT
EFFECT
Apr 29, 2026
S-3
SHELF
Apr 21, 2026
Full SEC filing analysis available with free account →
📰 Recent News
No recent news
🔬 More Research for PAVM
📊 PAVM FDA Catalyst Timeline & Biotech Grade — BiotechSigns
📡 PAVM Signal Convergence & Dark Pool Activity — StonkWhisper
📄 PAVM Dilution Risk Analysis — Full In-Depth Report
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.